Compare Alphabet Inc Class A (GOOGL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Natera Inc. Common Stock — how do they compare? Alphabet Inc Class A trades at $342.18 (market cap $4.30T), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Alphabet Inc Class A is far larger — about 75.4× Natera Inc. Common Stock's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Natera Inc. Common Stock for 0 Days on average.
| GOOGL | NTRA | |
|---|---|---|
Market Cap | $4.30T | $57.03B |
Volume | 22,270,289 | 1,131,157 |
Sector | Media | Health |
52-Week High | $402.62 | $425.64 |
52-Week Low | $250.46 | $179.42 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.19T | $56.18B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $347.64, down 1.44% today, but maintains strong technical support near $344-$350. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 54.77% net margin. Recent earnings beats and strong analyst consensus support the bullish outlook, with 87% of analysts rating it a Buy. Technical indicators show bullish moving averages but overbought RSI conditions.
Alphabet presents a compelling investment case with strong AI-driven growth, consistent earnings outperformance, and dominant market positioning. Key risks include regulatory scrutiny, competitive pressures in AI, and market volatility. With a consensus price target of $430.96 representing 24% upside potential, the stock offers attractive long-term value despite short-term technical overbought conditions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
